Jasper Therapeutics Reports Q2 2026 Results, Issues Corporate Update

What Happened

• On August 14, 2026, Jasper Therapeutics, Inc. (JSPR) announced and furnished a press release reporting its financial results for the quarter ended June 30, 2026 and providing a corporate update. The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) of Form 8‑K.
• The press release is furnished as Exhibit 99.1 to the Form 8‑K; per the filing it is furnished (not “filed”) in accordance with Form 8‑K General Instructions B.2 and therefore is not subject to Section 18 liability or automatically incorporated by reference into other SEC filings.

Key Details

• Date of disclosure: August 14, 2026.
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Format: Press release furnished as Exhibit 99.1 to the Current Report on Form 8‑K.
• Filing reference: Item 2.02 — Results of Operations and Financial Condition.

Why It Matters

• This 8‑K is how Jasper communicates its latest quarterly results and corporate progress to investors; the press release will contain the specific earnings, revenue, expense, cash position, or operational updates that matter to shareholders.
• Because the release is furnished (not filed), investors should read Exhibit 99.1 directly for the detailed numbers and statements, and note the limited legal filing status described in the Form 8‑K.